{
    "nctId": "NCT06534424",
    "briefTitle": "Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study",
    "officialTitle": "The caRe Study: Clinical Application of Refined Risk Estimates",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "HEALTH_SERVICES_RESEARCH",
    "enrollmentCount": 152,
    "primaryOutcomeMeasure": "Decisional conflict Regarding Cancer Risk Management",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Have had genetic counseling and testing for mutations in BRCA1 and/or BRCA2 through a Clinical Laboratory Improvement Act (CLIA)-certified laboratory\n* Were found to have a known pathogenic mutation upon testing\n* Are within 3 weeks of results disclosure\n* Have available medical records for ascertainment of clinical information\n* Are able to provide a source of deoxyribonucleic acid (DNA) (blood or mouthwash) for study\n* Have access to a telephone and a computer or other internet-ready device\n* Have not yet had a bilateral prophylactic mastectomy or bilateral Salpingo oophorectomy",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}